通过激活AKT/GSK3β通路,促进乳腺癌的进展
Linlin Fu1, Baodong Ma1, Lan Zhang1
1Department of Breast Surgery, Zhengzhou Central Hospital Affliated to Zhengzhou University, Zhengzhou, Henan, China.
Environmental toxicology
|August 7, 2024
概括
含有28 (TRIM28) 的三部分基因增强雌激素受体α (ERα) 活性,促进雌激素受体阳性乳腺癌 (BC) 细胞生长和进展. TRIM28可以作为BC治疗的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 雌激素受体α (ERα) 通过调节基因表达来驱动ER阳性乳腺癌 (BC) 的生长.
- 了解ERα相互作用对于开发向的BC疗法至关重要.
研究的目的:
- 在BC细胞中识别与染色质结合的ERα相互作用的蛋白质.
- 调查已识别的相互作用体在BC进展和信号通路中的作用.
主要方法:
- 快速免疫沉质谱和乙基化 (RIME) 用于在MCF7细胞中识别ERα相互作用体.
- 功能性试验评估TRIM28对BC细胞增殖,迁移和入侵的影响.
- 对AKT/GSK3β通路激活的分析.
主要成果:
- 确定了106种与ERα相关的蛋白质,其中含有28 (TRIM28) 的三方基因是最重要的.
- TRIM28增强了ERα转录活性,促进了BC细胞的增殖,迁移和入侵.
- 高TRIM28表达与ER阳性BC患者的不良临床结果相关,并激活AKT/GSK3β通路.
结论:
- TRIM28是一种关键的ERα相关蛋白质,促进BC进展.
- TRIM28调节ERα和AKT信号传递,代表了ER阳性BC的潜在治疗标.
更多相关视频
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
12.9K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
